Evidence map›Paper›PMID 40831878›Full record

ArticleCureus2025

Pulmonary Mucormycosis in Diabetic Patients: A Case Series From a Tertiary Respiratory Center in Sri Lanka.

Kasun T Maduranga, Arthihai Srirangan, P K E Diyalagoda, Sumudu Palihawadana, Eshantha Perara

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Pattern-based clinical recognition of diabetes-associatedFrontiers in cellular and infection microbiology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kasun T MadurangaDepartment of Pulmonary Medicine, National Hospital for Respiratory Diseases, Welisara, LKA.
Arthihai SriranganDepartment of Pulmonary Medicine, National Hospital for Respiratory Diseases, Welisara, LKA.
P K E DiyalagodaDepartment of Pulmonary Medicine, National Hospital for Respiratory Diseases, Welisara, LKA.
Sumudu PalihawadanaDepartment of Radiology, National Hospital for Respiratory Diseases, Welisara, LKA.
Eshantha PeraraDepartment of Pulmonary Medicine, National Hospital for Respiratory Diseases, Welisara, LKA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary mucormycosis is a rare but aggressive fungal infection that primarily affects immunocompromised individuals, especially those with uncontrolled diabetes mellitus. Its non-specific presentation can mimic more common pulmonary conditions, often resulting in delayed diagnosis and treatment. Here, we present a case series of three Sri Lankan patients with type 2 diabetes mellitus who developed pulmonary mucormycosis. Each case demonstrated variable respiratory and constitutional symptoms. Imaging, primarily chest radiography and contrast-enhanced CT, revealed findings such as cavitary lesions and pleural effusions. Diagnosis was confirmed via bronchoscopic or surgical sampling, with fungal stains showing broad, non-septate hyphae characteristic of mucormycosis. Two patients were successfully treated with prolonged intravenous liposomal amphotericin B therapy. One patient, however, rapidly deteriorated and died despite early antifungal initiation. This series underscores the importance of early clinical suspicion and tissue diagnosis in suspected invasive fungal infections among diabetic patients. In resource-limited and endemic settings, timely recognition and intervention remain crucial for improving patient outcomes.

Indexed as

histopathologic diagnosisliposomal amphotericin bpulmonary fungal infectionspulmonary mucormycosistype 2 diabetes mellitus

Identifiers

PMID40831878
PMCPMC12358222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.